COBRE Center for Cancer Research Development

这项修订后的竞争性更新建立在COBRE癌症研究发展中心（CCRD）成功指导有前途的初级研究人员走向独立的基础上。外部咨询委员会和高级教师指导和咨询委员会（EAC和SFMAC）将在指导初级研究人员方面发挥重要作用。蛋白质组学和分子病理学核心将继续提供先进技术和专家指导，这些资产将增强校外资金的竞争力。认识到罗德岛州的高癌症死亡率，CCRD将继续支持GI癌症领域的假设驱动研究。干细胞在肝脏/胃肠道肿瘤中的应用将由一个研究发展委员会监督。这个主题将充分利用罗德岛医院正在进行的强大的肝脏和干细胞研究项目。五位研究兴趣重叠的天才研究者将为分享想法和富有成效的互动创造机会。Chin博士将研究乙酰化依赖的STATS信号通路在人类和大鼠肝细胞癌中癌症干细胞自我更新和转移中的作用。Chatterjee博士于5年级加入CCRD，将专注于raf激酶抑制蛋白（RKIP），这是一种潜在的化疗易感性生物标志物，也是STAT3介导的人类结肠癌转移的抑制剂。Sanders博士，一位新的研究者，将研究从胎儿和成人肝脏分离的双能肝祖细胞的有丝分裂信号表型，以及这些途径如何受到成人肝脏微环境的影响。Altura博士，另一位新的研究者将研究乙酰化在survivin的定位、二聚化和活性中所起的作用，作为细胞分裂的调节剂和细胞凋亡的抑制剂。Moss博士是CCRD支持的研究者，他的第一个RO1将继续以胃因子-1/2为中心的新研究，这是他在COBRE资助的第一个周期中发现的两种新型肿瘤抑制基因。尽管扩大基础癌症研究仍将是癌症研究中心的主要任务，但我们将通过癌症研究中心之友增加筹款力度，并扩大旨在提高公众对癌症研究价值认识的外展活动。通过临床观察驱动的创新项目促进基础科学家和临床肿瘤学家之间的互动也将是重中之重。在未来5年，社区发展与发展中心将扩大其在与州和联邦立法机构及决策者保持对话方面的领导作用。CCRD将提供向NCI指定的临床癌症中心过渡所需的基础研究框架。

This revised competing renewal builds on the success of the COBRE Center for Cancer Research Development (CCRD) in guiding promising junior investigators towards independence. The External Advisory and Senior Faculty Mentoring and Advisory Committees (EAC and SFMAC) will play essential roles in mentoring of junior investigators. The Proteomics and Molecular Pathology Cores will continue to provide advanced technologies and expert guidance, assets that enhance competitiveness for extramural funds. Recognizing the high cancer mortality in Rhode Island, CCRD will continue to support hypothesis driven research in the area of GI Cancer. Development of new collaborative endeavors focused on stem cells in liver/GI cancer will be overseen by a Research Development Committee. This theme will take full advantage of the strong liver and stem cell research programs already ongoing at Rhode Island Hospital. Five talented investigators with overlapping research interests will generate opportunities for sharing of ideas and productive interaction. Dr. Chin will examine the role of acetylation dependent STATS signaling pathways in self-renewal and metastasis of cancer stem cells in human and rat hepatocellular carcinomas. Dr. Chatterjee, an investigator who joined CCRD in year 5, will focus on raf kinase inhibitory protein (RKIP), a potential biomarker for susceptibility to chemotherapy and an inhibitor of STAT3 mediated metastasis of human colon cancer. Dr. Sanders, a new investigator, will examine the mitogenic signaling phenotype of bipotent hepatic progenitors isolated from fetal and adult liver and how these pathways are influenced by the adult liver microenvironment. Dr. Altura, another new investigator will examine the role that acetylation plays in the localization, dimerization and activity of survivin as a regulator of cell division and an inhibitor of apoptosis. Dr. Moss, a CCRD supported investigator with his first RO1, will pursue a new line of research centered on gastrokine-1/2, two novel tumor suppressor genes identified during his first cycle of COBRE funding. Although expanding basic cancer research will continue to be the primary mission of CCRD, we will work through the Friends of CCRD to increase fundraising efforts and augment outreach activities aimed at increasing public awareness of the value of cancer research. Fostering interactions between basic scientists and clinical oncologists through innovative programs driven by clinical observation will also be a high priority. During the next 5 years, CCRD will expand its leadership role in sustaining a dialogue with State and Federal legislators and policy makers. CCRD will provide the basic research framework needed for transitioning into an NCI designated clinical cancer center.